CD86 and melanoma: Furthermore, analysis of the change in the expression of immune scMEP markers from iDC to mDC, revealed significant downregulation of CD86 and HLA-DR in melanoma patients with a progressive decrease in worse outcome group DC (Supplementary Fig. 4C).